Kalaya

New Active Relaxation Product Empowers Pain Sufferers to Overcome Stress, Anxiety, and Sleepless Nights

Retrieved on: 
Thursday, June 15, 2023
Melatonin, Feedback, Anxiety, Sugar, Sleep, Quality of life, Pain, Somnolence, Mental health, Human, Birth control, Nursing, Kalaya, Magnesium

TORONTO, June 15, 2023 (GLOBE NEWSWIRE) -- Canadians experiencing pain can now find solace in KaLaya's new, Vegan Blueberry Active Relaxation Gummies.

Key Points: 
  • TORONTO, June 15, 2023 (GLOBE NEWSWIRE) -- Canadians experiencing pain can now find solace in KaLaya's new, Vegan Blueberry Active Relaxation Gummies.
  • These gummies are designed to alleviate stress, anxiety, and sleepless nights, symptoms commonly experienced by Canadians with pain.
  • “One of the most common points of feedback we’ve heard from pain sufferers is just how significant a role pain can have on one’s sleep.
  • As we know, when you are deprived of sleep due to pain, that pain is perceived as worse.

Flora Growth Forms JV With Avaria Health and Beauty to Distribute Award-Winning Pain Products Across LATAM

Retrieved on: 
Friday, November 26, 2021
Other Health, Men, General Health, Discount, Variety, Specialty, Consumer, Convenience Store, Retail, Other Consumer, Women, Alternative Medicine, Health, Volunteering, Patient, Research, Sale, CEO, Environment, Technology, Industry, Forward-looking statement, Cannabis, Company, Arthralgia, IPO, FLGC, Tendinopathy, Nature, Pain, Kalaya, Emulsion, Flora, Oil, NASDAQ, Cannabidiol, Arthritis, Terminology, LATAM, Gel, Food, Growth, Cosmetics, Drug, Pharmaceutical industry, Risk management, Flora Growth’s Recent Financing, Avaria Health & Beauty Corp., Flora Growth Corp., FLORA GROWTH’S RECENT FINANCING, AVARIA HEALTH & BEAUTY CORP., FLORA GROWTH CORP.

Any profits from the sale of KaLaya products via FloVaria will be divided equally between Flora and Avaria, increasing the value of Floras existing distribution channels.

Key Points: 
  • Any profits from the sale of KaLaya products via FloVaria will be divided equally between Flora and Avaria, increasing the value of Floras existing distribution channels.
  • Further, Flora Lab will work to produce FloVarias cannabinoid-infused products, with an emphasis on incorporating cannabidiol (CBD), using cannabis from Floras cultivation facility.
  • Avaria has achieved impressive and continued growth of its KaLaya brand based on the quality and efficacy of the product.
  • Our team is very excited to bring their award-winning topical pain products to our LATAM distribution network, and to produce cannabinoid-infused KaLaya products at Flora Lab.

Flora Growth Reports H1 2021 Financial Results and Provides Guidance for H2 Revenue Anticipated Between US$9-11M

Retrieved on: 
Thursday, August 19, 2021
Textiles, Manufacturing, Alternative Medicine, Food, Beverage, Health, Cosmetics, Retail, Agriculture, Natural Resources, Union, Industry, Company, Webcast, Ernst Loosen, Nasdaq, Koch, Access to Cannabis for Medical Purposes Regulations, Growth, Kalaya, City, Traction, Science, Tobacco, FLGC, SEC, Letter, European Union, TROPI, Central, CPG, Cosmetics, Heimat, Colombians, Â, Marketing, Awareness, IPO, NASDAQ, OTC, Food, Cannabis, Partnership, CEO, Sale, Ã, Intention, Exercise, Drug, Security (finance), Fine chemical, Management, Animal

Flora Growth Corp. (NASDAQ:FLGC) (Flora, Flora Growth, or the Company), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, is pleased to report selected financial and operating results for the six-month period ending June 30, 2021 (all amounts expressed in US dollars, unless otherwise stated).

Key Points: 
  • Flora Growth Corp. (NASDAQ:FLGC) (Flora, Flora Growth, or the Company), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, is pleased to report selected financial and operating results for the six-month period ending June 30, 2021 (all amounts expressed in US dollars, unless otherwise stated).
  • Flora Growth generated revenues of +$2M with a gross profit of 60% (unaudited), as compared to revenues of ~$100K for 2020.
  • Flora Growth is a foreign private issuer and is required to submit financial results on a half-year basis, with a 6-month window to file the unaudited results.
  • Following the presentation, Flora will offer analysts, media, and investors the opportunity to ask questions in a question-and-answer session.

Colombia Challenges Canadian Cannabis Dominance

Retrieved on: 
Tuesday, August 10, 2021
Food, IBN, Gaping, Plant, Wall Street, Annual report, Private Securities Litigation Reform Act, Fear, CPG, THC, Justice, Kalaya, Acquisition, Growth, CGC, Cosmetics, Industry, Article, News, U.S. Securities and Exchange Commission, Drink, NNW, Securities Exchange Act of 1934, NOT, Time, Forward-looking statement, Aphria, Shoulder, Social media, Form 10-K, Flower, Coffee, History, NASDAQ, Securities Act of 1933, FNM, Canopy Growth, Overload, SMS, Review, Security (finance), CRON, Cannabis, Mouth, Letter, Water, Supreme, Tilray, FLGC, Certification, Partnership, Duque, Lois, Solution, ANY, Kasa, COVID-19, Awareness, Sundial, Textile, Drug, Retail

Colombia made history by modifying its cannabis laws, including allowing export of dried cannabis flower.

Key Points: 
  • Colombia made history by modifying its cannabis laws, including allowing export of dried cannabis flower.
  • Flora leverages cost-effective cannabis cultivation in Colombia to supply cannabis and its derivatives for portfolio of premium brands and products across several verticals.
  • Upon signing the decree, Duque quoted experts in saying legal cannabis will represent a $64 billion global market by 2024 while noting that cannabis will serve as a tool for "economic reactivation" in Colombia post the COVID-19 pandemic.
  • "According to a 2019 study, in Colombia, the cannabis sector generated 17.3 agricultural jobs per hectare," said Colombia's Minister of Justice Wilson Ruiz .

Colombia Challenges Canadian Cannabis Dominance

Retrieved on: 
Tuesday, August 10, 2021
Food, IBN, Gaping, Plant, Wall Street, Annual report, Private Securities Litigation Reform Act, Fear, CPG, THC, Justice, Kalaya, Acquisition, Growth, CGC, Cosmetics, Industry, Article, News, U.S. Securities and Exchange Commission, Drink, NNW, Securities Exchange Act of 1934, NOT, Time, Forward-looking statement, Aphria, Shoulder, Social media, Form 10-K, Flower, Coffee, History, NASDAQ, Securities Act of 1933, FNM, Canopy Growth, Overload, SMS, Review, Security (finance), CRON, Cannabis, Mouth, Letter, Water, Supreme, Tilray, FLGC, Certification, Partnership, Duque, Lois, Solution, ANY, Kasa, COVID-19, Awareness, Sundial, Textile, Drug, Retail

NEW YORK, Aug. 10, 2021 /PRNewswire/ -- In 2020, Canada became the largest exporter of dried cannabis flower in the world. Today, Canada is looking over its shoulder at a formidable competitor in Colombia, which recently instigated some legislative changes that position the country to become the global cannabis leader. Colombia was already recognized for its robust infrastructure, distribution and exports of certain cannabis products such as medicinal oils and extracts, but the country had a gaping hole in exports by keeping dried cannabis flower strictly verboten. That hole was filled on July 23, 2021, when Colombian President Ivan Duque signed a legislative decree ending the prohibition on the export of dried cannabis flower — a significant global market and a potential windfall for Flora Growth Corp. (NASDAQ: FLGC) (Profile) and its expansive global operations. The broader industry should also benefit from this latest development since most majors, including Canopy Growth Corporation (NASDAQ: CGC), Tilray Inc. (NASDAQ: TLRY), Cronos Group Inc. (NASDAQ: CRON) and Sundial Growers Inc. (NASDAQ: SNDL), support the mainstream worldwide evolution of legal cannabis.

Key Points: 
  • Colombia made history by modifying its cannabis laws, including allowing export of dried cannabis flower.
  • Flora leverages cost-effective cannabis cultivation in Colombia to supply cannabis and its derivatives for portfolio of premium brands and products across several verticals.
  • Upon signing the decree, Duque quoted experts in saying legal cannabis will represent a $64 billion global market by 2024 while noting that cannabis will serve as a tool for "economic reactivation" in Colombia post the COVID-19 pandemic.
  • "According to a 2019 study, in Colombia, the cannabis sector generated 17.3 agricultural jobs per hectare," said Colombia's Minister of Justice Wilson Ruiz .

Flora Growth to Partner with Avaria to Distribute Award-Winning Pain Cream Brand KaLaya Across LATAM & Produce Its CBD Formulations

Retrieved on: 
Tuesday, July 27, 2021
Alternative medicine, Retail, Health, Other Retail, Other Health, Specialty, Pharmaceutical, Airlines, Aviation, LATAM Airlines Group, LATAM Chile, Avaria, Kalaya, LATAM Brasil, Brand, Cannabis, Avaria Inc, Flora Growth Corp., AVARIA INC, FLORA GROWTH CORP.

Through the JV, Flora Growth will manage registration, sales, and distribution of KaLaya products in Colombia, Mexico, and other LATAM countries, while Avaria will supply finished product to the JV.

Key Points: 
  • Through the JV, Flora Growth will manage registration, sales, and distribution of KaLaya products in Colombia, Mexico, and other LATAM countries, while Avaria will supply finished product to the JV.
  • These products are expected to be distributed across LATAM using Flora Labs established distribution channels, with the aim of exporting to the U.S. market, where Avaria is currently launching the KaLaya brand.
  • Avaria does not currently hold a license in Canada to produce cannabis derived versions of its products at a commercial scale.
  • Avarias KaLaya pain cream brand has enjoyed strong success since inception, where it enjoys three consecutive years of triple digit growth through their industry leading Canadian e-commerce channels.